Bioventus Inc. (BVS) AI Stock Analysis

Bioventus Inc. develops and commercializes clinical treatments aimed at enhancing the body's natural healing processes. The company operates in the United States and internationally, offering non-surgical joint pain injection therapies and peripheral nerve stimulation products. It also provides surgical solutions including bone graft substitutes for spinal and orthopedic surgeries, alongside ultrasonic medical devices for bone sculpting, tumor removal, and tissue debridement. Its restorative portfolio features an ultrasonic bone healing system for fracture care, skin allografts, and chronic wound healing products, in addition to advanced rehabilitation devices for restoring leg or hand function across physician clinics, ambulatory surgery centers, and hospitals.

Bioventus recorded a 5-year revenue CAGR of 12.1% from FY2020 to FY2025. Annual revenue grew from $430.9M in FY2021 to $573.3M in FY2024, before revenue fell 0.9% to $568.1M in FY2025. After recording net losses of -$158.7M in FY2022, -$156.2M in FY2023, and -$33.5M in FY2024, net income recovered to $22.7M in FY2025 with an operating margin of 10.3%. Over the trailing twelve months, revenue reached $581.8M with an operating margin of 12.2% and profit margin of 9.4%. In the latest quarter ended June 30, 2026, quarterly revenue grew 3.8% year-over-year while quarterly earnings grew 327.3%.

As of June 30, 2026, Bioventus held $29.5M in cash and short-term investments against total debt of $263.7M, yielding net debt of $234.3M and a debt-to-equity ratio of 1.16. Total assets stood at $673.3M and shareholders' equity was $228.3M, with a current ratio of 1.69. Operating cash flow improved to $74.0M in FY2025 from $38.8M in FY2024, while free cash flow reached $71.4M. For FY2025, capital expenditures were $2.6M, while share count expanded 29.4% over 5 years.

Bioventus trades at a trailing P/E of 17.1x and a forward P/E of 14.8x, both below the median of its US-listed Healthcare peers of 24.6x and 17.3x, respectively. Its price-to-sales ratio of 1.6x is lower than the peer median of 4.1x, while its EV-to-EBITDA stands at 11.1x versus the peer median of 12.0x. Over the past year, BVS returned 93.3%, outperforming the S&P 500 SPY return of 16.8%. Over a 5-year period, BVS declined 2.5%, compared to an 83.0% gain for the S&P 500 SPY.

Wall Street coverage consists of 3 Strong Buy and 2 Buy recommendations, with 0 Hold, Sell, or Strong Sell ratings. The mean price target of $17.60 implies an upside of 32.3% from the last close of $13.30. For the fiscal year ending December 31, 2026, analysts estimate revenue of $604.8M and EPS of $0.78, representing 14.4% EPS growth. The company beat EPS estimates in 3 of the last 4 quarters, with the next earnings report scheduled for November 3, 2026.

This page is an AI-written research summary of Bioventus Inc. (BVS). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: BVS income statement, BVS balance sheet, BVS key metrics, BVS analyst forecast, BVS chart. See the BVS stock overview for the latest quote and news.